国家医疗保障局开展真实世界医保综合价值评价试点工作 这里是《21健讯Daily》，欢迎与21世纪经济报道新健康团队共同关注医药健康行业最新事件！ 政策动向 9月23日，国家医疗保障局办公室发布《关于开展真实世界医保综合价值评价试点工作的通知》。通知 提出，试点先行地区要在国家医保局统一部署下，按照"顶层设计、实践验证、决策应用"的工作思路， 通过在评价规范标准、技术方法、应用场景的实践探索以及相关数据、人才支撑体系拓展建设，到2027 年底，推进十个选题的研究落地，形成一套以价值为导向、基于真实世界研究的医保综合价值评价体 系，并在全国范围推广。 21点评：这是一场涉及理念、技术和制度的系统性变革。通过构建科学的评价体系、优化数据治理、深 化三医联动等，试点将推动医保从"被动支付"向"主动购买价值"转型，提高医保基金使用效率，赋能医 药行业高质量发展。 药械审批 恒瑞医药：阿得贝利单抗注射液新适应症上市许可申请获国家药监局受理 9月23日，恒瑞医药(600276.SH)公告称，公司子公司上海盛迪医药有限公司收到国家药监局下发的《受 理通知书》，公司阿得贝利单抗注射液新适应症的药品上市许可申请获国家药监局受理。 ...

每经AI快讯，东方海洋9月23日晚间发布公告称，山东东方海洋科技股份有限公司子公司质谱生物科技 有限公司自主研发的脂溶性维生素测定试剂盒于近日取得了山东省药品监督管理局的注册批准，获得医 疗器械注册证。产品名称为"脂溶性维生素测定试剂盒"。 每经头条（nbdtoutiao）——报价太低遭严防，投标企业还得"解释清楚"，一场国家组织的大型采购， 为何引发全行业关注 （记者 曾健辉） ...

Group 1: Company Developments - Hengqin Bihua Medical Laboratory successfully passed the ISO15189 accreditation site review, indicating that its quality management system and testing capabilities meet international standards [5] - Zhenjiankang Company received NMPA Class III medical device registration for two innovative products, bringing its total to seven Class III and four Class II medical device registrations [6] - Guangdong Taiwen Biological Engineering Co., Ltd. obtained a Class II medical device production license, marking compliance with national regulatory requirements in the field of in vitro diagnostic reagents [7] Group 2: Industry Initiatives - The dual-currency payment pilot program has expanded to six key commercial areas in Hengqin, facilitating small payments in both RMB and MOP, enhancing consumer experience [8] - The revised management measures for the Hengqin Guangdong-Macao Deep Cooperation Zone government investment fund were published, effective from August 13, 2025, focusing on key industry projects [9] - The newly issued support measures for financing development of small and micro enterprises in Hengqin include interest subsidies and risk compensation, with a maximum single financing risk compensation of 7.2 million yuan [10][11]